NZ609490A - Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt - Google Patents

Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt

Info

Publication number
NZ609490A
NZ609490A NZ609490A NZ60949011A NZ609490A NZ 609490 A NZ609490 A NZ 609490A NZ 609490 A NZ609490 A NZ 609490A NZ 60949011 A NZ60949011 A NZ 60949011A NZ 609490 A NZ609490 A NZ 609490A
Authority
NZ
New Zealand
Prior art keywords
phthalazin
pyrido
triazol
fluorophenyl
dihydro
Prior art date
Application number
NZ609490A
Other languages
English (en)
Inventor
Bing Wang
Daniel Chu
Yongbo Liu
Shichun Peng
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ609490(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of NZ609490A publication Critical patent/NZ609490A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ609490A 2010-10-21 2011-10-20 Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt NZ609490A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40547610P 2010-10-21 2010-10-21
PCT/US2011/057039 WO2012054698A1 (en) 2010-10-21 2011-10-20 Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt

Publications (1)

Publication Number Publication Date
NZ609490A true NZ609490A (en) 2015-06-26

Family

ID=44903424

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609490A NZ609490A (en) 2010-10-21 2011-10-20 Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt

Country Status (24)

Country Link
US (3) US8735392B2 (https=)
EP (2) EP3757106A1 (https=)
JP (6) JP2013540158A (https=)
KR (4) KR20180069132A (https=)
CN (1) CN103282365B (https=)
AR (1) AR083502A1 (https=)
AU (2) AU2011317040B2 (https=)
BR (1) BR112013009117A2 (https=)
CA (1) CA2814581C (https=)
CY (1) CY1123356T1 (https=)
DK (1) DK2630146T3 (https=)
ES (1) ES2816600T3 (https=)
HU (1) HUE051535T2 (https=)
IL (2) IL225789B (https=)
MX (1) MX362563B (https=)
NZ (1) NZ609490A (https=)
PL (1) PL2630146T3 (https=)
PT (1) PT2630146T (https=)
RU (1) RU2598606C3 (https=)
SG (2) SG189939A1 (https=)
SI (1) SI2630146T1 (https=)
TW (2) TWI557123B (https=)
WO (1) WO2012054698A1 (https=)
ZA (1) ZA201302810B (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
PT2533640T (pt) 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
NZ609490A (en) 2010-10-21 2015-06-26 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2742030B1 (de) * 2011-08-11 2016-07-27 Bayer Intellectual Property GmbH 1,2,4-triazolyl-substituierte ketoenole zum einsatz im pflanzenschutz
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
BR122023021436A2 (pt) * 2014-03-14 2023-12-12 Les Laboratoires Servier Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
SG11201700734RA (en) * 2014-07-31 2017-02-27 Medivation Technologies Inc Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
CN108883115A (zh) * 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
KR20200071097A (ko) 2017-10-13 2020-06-18 메르크 파텐트 게엠베하 Parp 억제제 및 pd-1 축 결합 길항제의 조합
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11368702B2 (en) 2018-06-04 2022-06-21 Lg Electronics, Inc. Method and device for processing video signal by using affine motion prediction
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US10942500B2 (en) * 2018-06-11 2021-03-09 Purdue Research Foundation System architecture and method of processing data therein
US10284866B1 (en) * 2018-07-02 2019-05-07 Tencent America LLC Method and apparatus for video coding
WO2020014700A1 (en) 2018-07-13 2020-01-16 Magic Leap, Inc. Systems and methods for display binocular deformation compensation
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3876940A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
CA3201467A1 (en) 2020-11-13 2022-05-19 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
JP2023551968A (ja) 2020-12-07 2023-12-13 ファイザー・インク タラゾパリブでの処置に対して感受性のある腫瘍を同定する方法およびその処置方法
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
RU2292337C2 (ru) * 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規ｐａｒｐ阻害剤
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
WO2004105700A2 (en) 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
TW200533664A (en) 2004-02-18 2005-10-16 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2010536807A (ja) 2007-08-22 2010-12-02 ４エスツェー アクチェンゲゼルシャフト キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン
WO2009099736A2 (en) 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
US20110301350A1 (en) 2008-08-12 2011-12-08 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
NZ609490A (en) 2010-10-21 2015-06-26 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
TW201605814A (zh) 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
SG11201700734RA (en) 2014-07-31 2017-02-27 Medivation Technologies Inc Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Also Published As

Publication number Publication date
IL271497A (en) 2020-02-27
KR20180069132A (ko) 2018-06-22
JP2019034951A (ja) 2019-03-07
WO2012054698A1 (en) 2012-04-26
MX2013004195A (es) 2013-07-22
CN103282365B (zh) 2017-12-29
TW201713656A (en) 2017-04-16
EP2630146B1 (en) 2020-07-01
IL225789B (en) 2019-12-31
US20180009806A1 (en) 2018-01-11
PT2630146T (pt) 2020-07-20
JP2020169209A (ja) 2020-10-15
US10189837B2 (en) 2019-01-29
DK2630146T3 (da) 2020-08-10
MX362563B (es) 2019-01-25
CA2814581C (en) 2019-02-12
KR20140009181A (ko) 2014-01-22
KR20210028747A (ko) 2021-03-12
AR083502A1 (es) 2013-02-27
PL2630146T3 (pl) 2020-11-02
SI2630146T1 (sl) 2020-12-31
US20140228369A1 (en) 2014-08-14
ES2816600T3 (es) 2021-04-05
JP2017061526A (ja) 2017-03-30
RU2598606C3 (ru) 2021-12-20
AU2011317040B2 (en) 2016-12-08
RU2013123036A (ru) 2014-11-27
US8735392B2 (en) 2014-05-27
JP2013540158A (ja) 2013-10-31
AU2017201564B2 (en) 2019-05-09
SG10201710578TA (en) 2018-02-27
AU2011317040A1 (en) 2013-05-09
TW201307345A (zh) 2013-02-16
RU2598606C2 (ru) 2016-09-27
US20120129865A1 (en) 2012-05-24
CN103282365A (zh) 2013-09-04
IL225789A0 (en) 2013-06-27
EP3757106A1 (en) 2020-12-30
TWI557123B (zh) 2016-11-11
JP2022140637A (ja) 2022-09-26
ZA201302810B (en) 2014-06-25
TWI643858B (zh) 2018-12-11
HUE051535T2 (hu) 2021-03-01
AU2017201564A1 (en) 2017-03-23
SG189939A1 (en) 2013-06-28
KR20190120458A (ko) 2019-10-23
BR112013009117A2 (pt) 2016-07-19
CY1123356T1 (el) 2021-12-31
JP2024150772A (ja) 2024-10-23
CA2814581A1 (en) 2012-04-26
EP2630146A1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
NZ609490A (en) Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
JP2013540158A5 (https=)
Aisawa et al. Intercalation behavior of l-ascorbic acid into layered double hydroxides
JP2017061526A5 (https=)
CA2682859A1 (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals
RU2018101363A (ru) Кристаллическая форма свободного основания лорлатиниба
JP2015010091A5 (https=)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2017039702A5 (https=)
Park et al. Functionalized mesoporous silicas with crown ether moieties for selective adsorption of lithium ions in artificial sea water
WO2012035544A3 (en) A novel polymorphic form of rifaximin and process for its preparation
IL184866A0 (en) Treatment of metastasized tumors
Dubey et al. Single-step green synthesis of imine-functionalized carbon spheres and their application in uranium removal from aqueous solution
JP2012533539A5 (https=)
Zima et al. Synthesis and characterization of copper 4-carboxyphenylphosphonates
Liu et al. Synthesis and Anticancer Properties of Rare Earth Substituted Tungstophosphoric Polyoxometalate Containing 5‐Fluorouracil
CA2814907C (en) Crystalline form of 13-[(n-tert-butoxycarbonyl)-2'-o-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin iii
Zhao et al. Synthesis, crystal structure and anti-tumor properties of fluorine-containing curcumin analogues
김현구 et al. Improvement of the formation and the thermal properties of CaTiO3 fabricated from a CaO-TiO2 mixture by using the mechanochemical method
HK1188783A (zh) 結晶的(8s，9r)-5-氟-8-(4-氟苯基)-9-(1-甲基-1h-1，2，4-三唑-5-基)-8，9-二氫-2h-吡啶並[4，3，2-de]酞嗪-3(7h)-酮甲苯磺酸鹽
GUO Synthesis of novel matrine derivatives and their in vitro anti-inflammatory activity
Paixão et al. Green synthesized copper nanoparticles into granular activated carbon of babassu coconut by Hibiscus Sabdariffa flowers for removal of nitrate
Shin et al. Synthesis and structural characterization of aluminogermanate pharmacosiderites with different crystal symmetries
WO2010046929A3 (en) Novel polymorphic forms of temazepam and processes for preparing the same
Guelachvili et al. Table 114. H218O (H18OH): Experimental and calculated wavenumber, and intensity for the (110)–(000) transitions in the range 4735–5845 cm–1: Molecular Constants

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20151218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2017 BY THOMSON REUTERS

Effective date: 20160909

ASS Change of ownership

Owner name: MEDIVATION TECHNOLOGIES, INC., US

Effective date: 20161013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2018 BY THOMSON REUTERS

Effective date: 20170919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2019 BY THOMSON REUTERS

Effective date: 20180917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2020 BY THOMSON REUTERS

Effective date: 20190917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2022 BY THOMSON REUTERS

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2023 BY THOMSON REUTERS

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2024 BY THOMSON REUTERS

Effective date: 20230904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2025 BY THOMSON REUTERS

Effective date: 20240903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 OCT 2026 BY THOMSON REUTERS

Effective date: 20250901